Phase 3 study presentations in SLE to show efficacy results across multiple clinical endpoints, including low disease ...

A trial emulation assessed whether GLP-1RA use improves cardiovascular, kidney, and death outcomes in patients with systemic lupus erythematosus, including lupus nephritis.

Telitacicept, a new dual inhibitor of the cytokines B-lymphocyte stimulator (BLyS) and APRIL (a proliferation-inducing ligand ...

Recommendation based on TULIP-SC Phase III trial results showing first-in-class Saphnelo reduced disease activity via once-weekly subcutaneous administration AstraZeneca's Saphnelo (anifrolumab) has ...

Researchers at the First Affiliated Hospital of the University of Science and Technology of China claim that an in vivo CD8 T-cell-targeted lipid nanoparticle carrying CD19 CAR mRNA (HN2301) generated ...

Saphnelo can now be administered subcutaneously rather than intravenously following the European regulator’s recommendation.

Objective Peer mentoring has been shown to be an effective intervention for chronic conditions with evidence to suggest that ...

Trial met primary endpoint achieving statistically significant improvement in disease activity, with 67.1% of patients responding with ...

With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...

Eventual tapering and withdrawal of steroids in patients with lupus nephritis is recommended to minimize the drugs' adverse ...

A new study has found that women with systemic lupus erythematosus who have problems with memory and thinking (mild cognitive impairment, or MCI) exhibit morphological brain changes.

AstraZeneca has announced that Saphnelo (anifrolumab) has been recommended for approval in the European Union (EU) as a ...